Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations.

Saved in:
Bibliographic Details
Title: Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations.
Authors: Hendy DA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Pena ES; Joint Department of Biomedical Engineering University of North Carolina at Chapel Hill and North Carolina State University Chapel Hill North Carolina USA., Ontiveros-Padilla L; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Dixon TA; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Middleton DD; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Williamson GL; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Lukesh NR; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Simpson SR; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Stiepel RT; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Islam MJ; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Carlock MA; Florida Research and Innovation Center Port St. Lucie Florida USA., Ross TM; Florida Research and Innovation Center Port St. Lucie Florida USA.; Center for Vaccines and Immunology University of Georgia Athens Georgia USA.; Department of Infectious Diseases University of Georgia Athens Georgia USA., Bachelder EM; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA., Ainslie KM; Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA.; Joint Department of Biomedical Engineering University of North Carolina at Chapel Hill and North Carolina State University Chapel Hill North Carolina USA.; Department of Microbiology and Immunology, UNC School of Medicine University of North Carolina Chapel Hill North Carolina USA.
Source: Bioengineering & translational medicine [Bioeng Transl Med] 2023 Dec 08; Vol. 9 (2), pp. e10634. Date of Electronic Publication: 2023 Dec 08 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: John Wiley & Sons Inc Country of Publication: United States NLM ID: 101689146 Publication Model: eCollection Cited Medium: Print ISSN: 2380-6761 (Print) Linking ISSN: 23806761 NLM ISO Abbreviation: Bioeng Transl Med Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2380-6761
DOI:10.1002/btm2.10634